Wells Fargo & Company MN Has $5.03 Million Stock Holdings in DaVita Inc. (NYSE:DVA)

Wells Fargo & Company MN trimmed its position in DaVita Inc. (NYSE:DVA - Free Report) by 38.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,607 shares of the company's stock after selling 20,692 shares during the quarter. Wells Fargo & Company MN's holdings in DaVita were worth $5,026,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its stake in shares of DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock valued at $99,846,000 after acquiring an additional 92,014 shares during the last quarter. Amundi increased its stake in DaVita by 116.4% in the fourth quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after purchasing an additional 240,126 shares in the last quarter. KBC Group NV raised its holdings in DaVita by 0.8% in the fourth quarter. KBC Group NV now owns 316,155 shares of the company's stock worth $47,281,000 after purchasing an additional 2,636 shares during the period. Nordea Investment Management AB boosted its position in shares of DaVita by 4.9% during the fourth quarter. Nordea Investment Management AB now owns 264,535 shares of the company's stock worth $39,712,000 after purchasing an additional 12,339 shares in the last quarter. Finally, California Public Employees Retirement System increased its position in shares of DaVita by 75.1% in the 4th quarter. California Public Employees Retirement System now owns 196,788 shares of the company's stock valued at $29,430,000 after buying an additional 84,375 shares in the last quarter. 90.12% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on DVA. Sanford C. Bernstein set a $184.00 price target on DaVita in a research report on Friday, February 21st. StockNews.com upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Thursday, April 10th. Cowen restated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Barclays upped their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, DaVita presently has an average rating of "Hold" and an average price target of $166.33.

DaVita Stock Down 1.4 %

NYSE DVA traded down $1.99 during trading hours on Friday, hitting $137.57. 104,979 shares of the company traded hands, compared to its average volume of 837,075. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The business's 50-day moving average is $146.81 and its 200-day moving average is $155.40. The stock has a market capitalization of $11.01 billion, a price-to-earnings ratio of 12.80, a P/E/G ratio of 1.07 and a beta of 1.04. DaVita Inc. has a twelve month low of $130.96 and a twelve month high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Sell-side analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.